Cite
MLA Citation
Matthew D Hellmann et al.. “Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.” Lancet oncology, vol. 18, no. 1, n.d., pp. 31–41. http://access.bl.uk/ark:/81055/vdc_100039989298.0x000024